Neuren Pharmaceuticals Limited

OTCPK:NURP.F Stock Report

Market Cap: US$1.0b

Neuren Pharmaceuticals Valuation

Is NURP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NURP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NURP.F ($7.95) is trading below our estimate of fair value ($13.2)

Significantly Below Fair Value: NURP.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NURP.F?

Key metric: As NURP.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NURP.F. This is calculated by dividing NURP.F's market cap by their current earnings.
What is NURP.F's PE Ratio?
PE Ratio13.5x
EarningsAU$117.29m
Market CapAU$1.57b

Price to Earnings Ratio vs Peers

How does NURP.F's PE Ratio compare to its peers?

The above table shows the PE ratio for NURP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.2x
COLL Collegium Pharmaceutical
11.2x22.0%US$1.0b
BSEM BioStem Technologies
14.2x33.8%US$224.4m
HRMY Harmony Biosciences Holdings
16.6x32.8%US$2.0b
PAHC Phibro Animal Health
54.9x60.0%US$961.2m
NURP.F Neuren Pharmaceuticals
13.5x-9.9%US$1.6b

Price-To-Earnings vs Peers: NURP.F is good value based on its Price-To-Earnings Ratio (13.5x) compared to the peer average (24.2x).

Price to Earnings Ratio vs Industry

How does NURP.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.5xn/aUS$1.78b
KPRX Kiora Pharmaceuticals
1.9x-40.4%US$10.35m
EDXC Endexx
0.9xn/aUS$6.03m
CNNC Cannonau
0.7xn/aUS$241.82k
NURP.F 13.5xIndustry Avg. 19.8xNo. of Companies8PE01224364860+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NURP.F is good value based on its Price-To-Earnings Ratio (13.5x) compared to the US Pharmaceuticals industry average (19.3x).

Price to Earnings Ratio vs Fair Ratio

What is NURP.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NURP.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NURP.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NURP.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.95
US$17.06
+114.6%
16.4%US$20.13US$12.36n/a6
Nov ’25US$8.97
US$17.92
+99.8%
11.4%US$20.18US$15.45n/a6
Oct ’25US$10.33
US$18.01
+74.3%
11.4%US$20.27US$15.53n/a6
Sep ’25US$10.20
US$18.01
+76.5%
11.4%US$20.27US$15.53n/a6
Aug ’25US$13.50
US$19.32
+43.1%
8.1%US$21.15US$16.84n/a6
Jul ’25US$14.25
US$19.05
+33.7%
7.7%US$20.68US$16.68n/a6
Jun ’25US$14.00
US$18.99
+35.7%
7.7%US$20.62US$16.63n/a6
May ’25US$12.51
US$17.38
+38.9%
9.7%US$20.15US$14.82n/a5
Apr ’25US$13.45
US$17.38
+29.2%
9.7%US$20.15US$14.82n/a5
Mar ’25US$12.00
US$17.38
+44.8%
9.7%US$20.15US$14.82n/a5
Feb ’25US$15.56
US$17.85
+14.7%
5.2%US$18.79US$16.32n/a4
Jan ’25US$16.98
US$17.87
+5.3%
4.5%US$18.41US$16.50n/a4
Dec ’24US$9.97
US$13.12
+31.6%
9.3%US$14.84US$11.40n/a4
Nov ’24US$6.69
US$12.18
+82.1%
9.5%US$14.14US$11.14US$8.974
Oct ’24US$7.36
US$10.79
+46.6%
31.4%US$14.39US$4.35US$10.335
Sep ’24US$7.96
US$10.79
+35.6%
31.4%US$14.39US$4.35US$10.205
Aug ’24US$9.57
US$11.02
+15.2%
31.7%US$15.23US$4.58US$13.505
Jul ’24US$8.00
US$9.33
+16.6%
31.2%US$12.22US$4.49US$14.255
Jun ’24US$8.85
US$9.33
+5.4%
31.5%US$12.26US$4.50US$14.005
May ’24US$9.43
US$8.97
-4.8%
31.4%US$12.29US$4.51US$12.515
Apr ’24US$9.12
US$8.97
-1.6%
31.4%US$12.29US$4.51US$13.455
Mar ’24US$4.82
US$5.54
+14.9%
7.2%US$5.85US$4.98US$12.003
Feb ’24US$5.49
US$5.64
+2.8%
6.1%US$6.04US$5.20US$15.563
Jan ’24US$5.45
US$5.09
-6.5%
9.7%US$5.59US$4.42US$16.983
Dec ’23US$5.50
US$5.09
-7.3%
9.7%US$5.59US$4.42US$9.973
Nov ’23US$4.80
US$5.09
+6.1%
9.7%US$5.59US$4.42US$6.693

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.4%

1Y

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7D

7.8%

1Y

20.6%

IQVIA Holdings

US$36.5b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

3.6%

1Y

-5.8%